Anthropic, the creator of AI chatbot Claude, has partnered with six leading biotech companies to revolutionize drug discovery and potentially eradicate diseases such as cancer, food allergies, and rare conditions. The initiative aims to expedite various stages of medicine development through artificial intelligence (AI).
One significant project involves Generate Biomedicines, which is adapting CAR T-cell therapy – traditionally used against blood cancers – for the treatment of solid tumors. Using Claude Code, six scientists from Generate proposed a redesigned version of a section of the therapy's genetic instructions, resulting in a shorter design that increased immune cell receptor production and extended their longevity.
Another collaboration with BigHat Biosciences focuses on enhancing two potential drug candidates, including one designed to target cancer cells. After testing over 1,000 variations, researchers found the best version bound to its target more than ten times as tightly as the original.
In addition, Anthropic's work with Divergence Labs produced around 35,000 antibody designs in a single month to develop a potential treatment for food allergies. Separately, its collaboration with Enveda reduced the time required for human review of manufacturing documents by 89%.
Anthropic has also embarked on drug discovery programs focusing on rare childhood forms of muscular dystrophy. One candidate could enter human clinical trials as early as late 2028, provided the promising results continue to hold up. However, much of this research remains at the preclinical stage.
[blank line]
Anthropic, the company behind AI chatbot Claude, has joined forces with six biotechnology organizations to explore the potential of artificial intelligence (AI) in speeding up different stages of medicine development. The collaborations aim to leverage AI for identifying potential drugs, designing molecules, and reducing research time and costs.
Generate Biomedicines is one partner working to adapt CAR T-cell therapy – conventionally used against blood cancers – for solid tumors. Using Claude Code, six scientists from Generate proposed a redesigned version of a section of the therapy's genetic instructions, resulting in a shorter design that boosted immune cell receptor production and extended their longevity.
Another partner, BigHat Biosciences, is focusing on improving two potential drug candidates, including one designed to target cancer cells. After testing over 1,000 variations, researchers found the best version bound to its target more than ten times as tightly as the original.
In another project, Anthropic's work with Divergence Labs resulted in around 35,000 antibody designs in a single month for developing a potential treatment for food allergies. Separately, its collaboration with Enveda significantly reduced the time required for human review of manufacturing documents.
[blank line]
Anthropic has announced collaborations with six leading biotech companies to utilize artificial intelligence (AI) in developing potential treatments for various diseases, including cancer, food allergies, and rare conditions. These partnerships aim to expedite different stages of medicine development through AI.
One project involves Generate Biomedicines, which is adapting CAR T-cell therapy – traditionally used against blood cancers – for solid tumors. Using Claude Code, six scientists from Generate proposed a redesigned version of a section of the therapy's genetic instructions, resulting in a shorter design that improved immune cell receptor production and extended their longevity.
Another collaboration with BigHat Biosciences focuses on enhancing two potential drug candidates, including one designed to target cancer cells. After testing over 1,000 variations, researchers found the best version bound to its target more than ten times as tightly as the original.
In another development, Anthropic's work with Divergence Labs produced around 35,000 antibody designs in a single month for developing a potential treatment for food allergies. Separately, its collaboration with Enveda significantly reduced the time required for human review of manufacturing documents.
[blank line]
Anthropic is stepping up efforts to use artificial intelligence (AI) in accelerating drug discovery, partnering with six biotechnology companies to develop potential treatments for cancer, food allergies, and rare diseases. The company behind AI chatbot Claude aims to expedite various stages of medicine development through AI.
Generate Biomedicines is one collaborator working on adapting CAR T-cell therapy – conventionally used against blood cancers – for solid tumors. Using Claude Code, six scientists from Generate proposed a redesigned version of a section of the therapy's genetic instructions, resulting in a shorter design that boosted immune cell receptor production and extended their longevity.
Another partner, BigHat Biosciences, is focusing on improving two potential drug candidates, including one designed to target cancer cells. After testing over 1,000 variations, researchers found the best version bound to its target more than ten times as tightly as the original.
In another project, Anthropic's work with Divergence Labs resulted in around 35,000 antibody designs in a single month for developing a potential treatment for food allergies. Separately, its collaboration with Enveda significantly reduced the time required for human review of manufacturing documents.
Anthropic has also embarked on drug discovery programs focusing on rare childhood forms of muscular dystrophy, with one candidate potentially entering human clinical trials as early as late 2028. However, much of this research remains at the preclinical stage.